Clinical Trials Results - National Cancer Institute

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

In English \| En español
Search

NCI Home

Cancer Topics


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 77 for your search:

Drug:  goserelin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: D6876C00001, NCT00293696

Phase III Randomized Study of Adjuvant Tamoxifen With or Without Ovarian Suppression and/or Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) in Premenopausal Women With Stage I-IIIA, Unilateral, Invasive Breast Cancer (Summary Last Modified 12/2001)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 70 and under
Sponsor:
Protocol IDs: SCTN-BR9401, EU-94002, UKCCCR-ABC/BR9401, NCT00002580

Phase III Randomized Study of Adjuvant Tamoxifen, Ovarian Suppression, and/or Chemotherapy in Women With Stage I, II, and IIIA Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor:
Protocol IDs: NCRI-ABC, CRC-TU-BR3010, SCTN-BR9401/BR9402, YRCO-ABC, EU-94029, UKCCCR-ABC, NCT00002582

Phase III Randomized Study of Adjuvant Tamoxifen with vs without Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer 3 cm or Less in Diameter (Summary Last Modified 03/98)

Phase: Phase III
Type: Treatment
Status: Completed
Age: premenopausal
Sponsor: NCI
Protocol IDs: E-3193, CLB-9494, NCCTG-933252, SWOG-9347, INT-0142, E3193

Phase III Randomized Study of Radiotherapy With or Without Neoadjuvant Flutamide Plus Goserelin or Leuprolide in Patients With Good Prognosis, Locally Confined Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: NCI
Protocol IDs: RTOG-9408, NCT00002597, RTOG-94-08

Phase III Randomized Study of Whole-Pelvic Irradiation Followed by a Cone-Down Boost to the Prostate vs Prostate Irradiation Only and of Neoadjuvant vs Adjuvant FLUT/ZDX for Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor: NCI
Protocol IDs: RTOG-9413, RTOG-94-13, NCT00769548

Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 80
Sponsor: NCI
Protocol IDs: CAN-NCIC-PR3, CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3

Phase III Randomized Study of Adjuvant Cyclophosphamide/Methotrexate/Fluorouracil (CMF) vs Total Estrogen Blockade for Pre-/Perimenopausal Women with ER-Positive, Stage II Breast Cancer with 1-9 Positive Nodes (Summary Last Modified 10/98)

Phase: Phase III
Type: Treatment
Status: Closed
Age: pre/perimenopausal 30 and over
Sponsor:
Protocol IDs: CNR-GROCTA-010209, EU-93018

Phase III Randomized Study of Radical Prostatectomy with vs without Neoadjuvant Hormone Therapy Using Leuprolide or Goserelin and Flutamide or Bicalutamide for Stage I/II Prostate Cancer (Summary Last Modified 08/98)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: SWOG-S9615, SWOG-9615, S9615

10.

Phase III Randomized Study of Orchiectomy or LHRH Analogue Plus Flutamide With or Without Suramin and Hydrocortisone in Advanced Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-8892, CLB-E8892, SWOG-E8892, NCT00002881, E8892

11.

Phase III Study of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive Adenocarcinoma of the Prostate (Summary Last Modified 11/98)

Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: RTOG-9608, RTOG-96-08

12.

Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CAN-NCIC-PR7, SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7

13.

Phase III Randomized Study of Adjuvant Androgen Deprivation Therapy With or Without Mitoxantrone and Prednisone After Radical Prostatectomy in Patients With High-Risk Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: 30 to 85
Sponsor: NCI
Protocol IDs: SWOG-S9921, CALGB-99904, S9921, NCT00004124

14.

Phase III Randomized Study of Oral Thalidomide Versus Placebo in Patients With Androgen-Dependent Nonmetastatic Prostate Cancer After Limited Hormonal Ablation

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0080, NCI-T99-0053, T99-0053, NCT00020085

15.

Phase III Randomized Study of Initial Bicalutamide Versus Observation Followed By Bicalutamide With Either Goserelin or Bilateral Orchiectomy in Patients With Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 80 and under
Sponsor: Other
Protocol IDs: EORTC-GU-30991, NCT00014586

16.

Phase III Randomized Study of Radiotherapy With or Without Adjuvant Bicalutamide and Goserelin in Patients With Localized Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 80 and under
Sponsor: Other
Protocol IDs: EORTC-22991, NCT00021450

17.

Phase III Zoladex Depot vs Surgical Castration in Patients with Stage D2 Prostate Carcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: AECM-8508170, NCI-V86-0027

18.

Phase III Randomized Study of Zoladex Depot vs Diethylstilbestrol in Patients with Stage D2 Prostate Carcinoma Who Have Refused Orchiectomy

Phase: Phase III
Type: Treatment
Status: Completed
Age: over 18
Sponsor:
Protocol IDs: AECM-8508171, NCI-V86-0028

19.

Phase III Immediate vs Delayed Endocrine Therapy with Zoladex and Cyproterone Acetate for Patients with pN1-3M0 Carcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: EORTC-30846

20.

Phase III Randomized Prospective Study of Orchidectomy vs Hormonal Therapy with an LHRH Analogue (Zoladex) plus an Anti-Androgen (Flutamide) in the Treatment of Patients with Metastatic Prostatic Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor:
Protocol IDs: EORTC-30853

21.

Phase III Hormonal Therapy with Zoladex Depot vs Diethylstilbestrol in Patients with Stage D2 Prostate Carcinoma Who Have Refused Orchiectomy

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: WCCC-CO-8583, NCI-V86-0038

22.

Phase III Comparison of Adjuvant Therapy with Zoladex vs Observation Only Following Definitive Radiotherapy for Unfavorable Prognosis Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor: NCI
Protocol IDs: RTOG-8531, RTOG-85-31

23.

Phase III Zoladex Depot vs Surgical Castration in Patients with Stage D2 Prostate Carcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: DCH-ZOL-56381, NCI-V86-0154

24.

Phase III Hormonal Therapy with Zoladex Depot vs Diethylstilbestrol in Patients with Stage D2 Prostate Carcinoma Who Have Refused Orchiectomy

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: DCH-ZOL-56382, NCI-V86-0159

25.

Phase III Randomized Double-Blind Trial of Antiandrogen Therapy with Anandron plus the LHRH Agonist Zoladex vs Placebo in Patients with Unresectable Hepatocellular Carcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: postpubertal
Sponsor:
Protocol IDs: EORTC-40861

Select All on Page

Help with Results

A Service of the National Cancer Institute